title: [Adjuvant chemotherapy comprising modified FOLFOX6 after curative resection of synchronous or metachronous metastasis from colorectal cancer].
abstract: OBJECTIVE
  This retrospective study evaluated the outcome of adjuvant chemotherapy comprising modified FOLFOX6 (mFOLFOX6) after potentially curative metastasectomy from colorectal cancer.
  
  
  METHODS
  The subjects were 40 patients with colorectal cancer who underwent potentially curative metastatectomy without any prior chemotherapy between December 2003 and November 2011. Patient background, type of adjuvant chemotherapy, and prognosis were examined.
  
  
  RESULTS
  Adjuvant chemotherapy was given in 30 patients (mFOLFOX6, n=26; oral fluoropyrimidines, n=4). The median relapse-free survival tended to be longer in patients treated with mFOLFOX6 compared to those treated with fluoropyrimidines (28.5 months vs 14.8 months; p=0.11). The median overall survival did not differ significantly between the 2 groups (37.9 months vs 31.3 months, p=0.56). When the analysis was restricted to patients treated with mFOLFOX6, no significant differences were found in relapse-free survival (p=0.46), overall survival (p=0.29), and frequency of adverse events during chemotherapy(Grade 3, p=0.32) between patients with synchronous metastasis(n=11) and those with metachronous metastasis (n=15).
  
  
  CONCLUSIONS
  These results suggest that mFOLFOX6 might contribute to prolonging the time to relapse and that the timing of developing metastasis(synchronously or metachronously) may not have any effect on the outcome of adjuvant mFOLFOX6.
authors.affiliation: Dept. of Digestive Tract and General Surgery, Saitama Medical University, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Hatano
authors.forename: Keiichiro
authors.initials: K
authors.lastname: Ishibashi
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Amano
authors.forename: Toru
authors.initials: T
authors.lastname: Ishiguro
authors.forename: Kouki
authors.initials: K
authors.lastname: Kuwabara
authors.forename: Jun
authors.initials: J
authors.lastname: Sobajima
authors.forename: Tomonori
authors.initials: T
authors.lastname: Ohsawa
authors.forename: Norimichi
authors.initials: N
authors.lastname: Okada
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Kumagai
authors.forename: Kensuke
authors.initials: K
authors.lastname: Kumamoto
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Baba
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Tsuji
authors.forename: Norihiro
authors.initials: N
authors.lastname: Haga
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Ishida
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D011379:Prognosis; D012189:Retrospective Studies
chemical_list: D009944:Organoplatinum Compounds; D002955:Leucovorin; D005472:Fluorouracil